168 related articles for article (PubMed ID: 2978926)
1. Anti-interleukin-2 receptor (IL-2R) antibody against rejection of organ grafts.
Kupiec-Weglinski JW; Padberg W; Uhteg LC; Towpik E; Lord RH; Ma L; Diamantstein T; Strom TB; Tilney NL
Transplant Proc; 1987 Feb; 19(1 Pt 1):591-3. PubMed ID: 2978926
[No Abstract] [Full Text] [Related]
2. Selective sparing of T suppressor cells by anti interleukin-2 receptor monoclonal antibodies (IL-2R mAbs) in vitro correlates with their therapeutic effects in vivo.
Tanaka K; Turka LA; Ueda H; Diamantstein T; Milford EL; Carpenter CB; Tilney NL; Kupiec-Weglinski JW
Transplant Proc; 1989 Feb; 21(1 Pt 1):475-6. PubMed ID: 2523145
[No Abstract] [Full Text] [Related]
3. Pretreatment with cyclosporin A (CyA) and anti-interleukin 2 receptor monoclonal antibody (IL-2R MAb) abrogates the anti-idiotype response in rat recipients of cardiac allografts.
Tanaka K; Kupiec-Weglinski JW; Hancock WW; Stunkel K; Diamantstein T; Tilney NL
Transplant Proc; 1991 Feb; 23(1 Pt 1):281-2. PubMed ID: 1990532
[No Abstract] [Full Text] [Related]
4. Identification of IL 2R+ T cells and macrophages within rejecting rat cardiac allografts, and comparison of the effects of treatment with anti-IL 2R monoclonal antibody or cyclosporin.
Hancock WW; Lord RH; Colby AJ; Diamantstein T; Rickles FR; Dijkstra C; Hogg N; Tilney NL
J Immunol; 1987 Jan; 138(1):164-70. PubMed ID: 3097143
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression in small bowel transplantation--treatment with a monoclonal IL-2 receptor antibody (NDS 61).
Schweizer E; Papachrysanthou A; Faendrich F; Deltz E; Schroeder P
Transplant Proc; 1994 Dec; 26(6):3142-3. PubMed ID: 7998095
[No Abstract] [Full Text] [Related]
6. Mechanism of action of interleukin-2 receptor (IL-2R) monoclonal antibody (MAb) therapy: target cell depletion or inhibition of function?
Tellides G; Dallman MJ; Morris PJ
Transplant Proc; 1989 Feb; 21(1 Pt 1):997-8. PubMed ID: 2650306
[No Abstract] [Full Text] [Related]
7. Prolongation of murine cardiac allograft survival by the anti-interleukin-2 receptor monoclonal antibody AMT-13.
Kirkman RL; Barrett LV; Koltun WA; Diamantstein T
Transplant Proc; 1987 Feb; 19(1 Pt 1):618-9. PubMed ID: 3274828
[No Abstract] [Full Text] [Related]
8. Peripheral blood monitoring during and after rejection-prophylaxis with a monoclonal anti-interleukin-2-receptor antibody in kidney and heart transplant recipients.
van Gelder T; Knoop CJ; Hesse CJ; Vaessen LM; Balk AH; Yzermans JN; Weimar W
Transplant Proc; 1995 Feb; 27(1):856-8. PubMed ID: 7879206
[No Abstract] [Full Text] [Related]
9. Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted immunotherapy. The action of anti-IL-2R monoclonal antibodies and synergistic effect of cyclosporin A.
Diamantstein T; Mouzaki A; Osawa H; Volk HD; Hahn HJ; Kirkman RL; Strom TB; Tilney NL; Kupiec-Weglinski JW
Dev Biol Stand; 1988; 69():177-84. PubMed ID: 3066671
[No Abstract] [Full Text] [Related]
10. Synergistic interactions between anti-interleukin-2 receptor (IL-2R) MAb and CyA in sensitized rat recipients of cardiac allografts.
Kupiec-Weglinski JW; Sablinski T; Hancock WW; Mix CT; Tilney NL
Transplant Proc; 1991 Feb; 23(1 Pt 1):285-6. PubMed ID: 1990533
[No Abstract] [Full Text] [Related]
11. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-gamma in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy.
Mottram PL; Han WR; Purcell LJ; McKenzie IF; Hancock WW
Transplantation; 1995 Feb; 59(4):559-65. PubMed ID: 7878761
[TBL] [Abstract][Full Text] [Related]
12. Treatment of presensitization with IL-2 receptor antibody plus alloantigen.
Tyler JD; Wierwille SL; Goldman MH
Transplant Proc; 1989 Feb; 21(1 Pt 1):1010-2. PubMed ID: 2650062
[No Abstract] [Full Text] [Related]
13. Effects of anti-IL 2 receptor monoclonal antibody and cyclosporine on IL 2 receptor-positive cells infiltrating cardiac allografts in the rat.
Lord RH; Hancock WW; Colby AJ; Padberg W; Diamantstein T; Kupiec-Weglinski JW; Tilney NL
Transplant Proc; 1987 Feb; 19(1 Pt 1):354-5. PubMed ID: 3079156
[No Abstract] [Full Text] [Related]
14. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 7 receptor alpha as a potential therapeutic target in transplantation.
Racapé M; Vanhove B; Soulillou JP; Brouard S
Arch Immunol Ther Exp (Warsz); 2009; 57(4):253-61. PubMed ID: 19585222
[TBL] [Abstract][Full Text] [Related]
16. Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression.
Gaweco AS; Otto G; Otto HF; Meuer S; Geisse T; Hofmann WJ
Transplant Proc; 1995 Feb; 27(1):1152-4. PubMed ID: 7533370
[No Abstract] [Full Text] [Related]
17. Functional blocking of the interleukin-2 receptor (IL-2R) may be important in the efficacy of IL-2R antibody therapy.
Tellides G; Dallman MJ; Kupiec-Weglinski JW; Diamantstein T; Morris PJ
Transplant Proc; 1987 Oct; 19(5):4231-3. PubMed ID: 3118538
[No Abstract] [Full Text] [Related]
18. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
[TBL] [Abstract][Full Text] [Related]
19. In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic.
Ramos EL; Leggat JE; Milford EL; Kirkman RL; Tilney NL; Strom TB; Shapiro ME; Waldmann TA; Carpenter CB
Trans Assoc Am Physicians; 1989; 102():231-9. PubMed ID: 2534707
[No Abstract] [Full Text] [Related]
20. Anti-interleukin-2 receptor monoclonal antibody therapy in rats: comparison of the effector mechanisms mediated by variant murine isotypes.
Stünkel KG; Grützmann R; Diamantstein T; Kupiec-Weglinski JW; Schlumberger HD
Transplant Proc; 1989 Feb; 21(1 Pt 1):1003-5. PubMed ID: 2784878
[No Abstract] [Full Text] [Related]
[Next] [New Search]
